Mostrar el registro sencillo del ítem
dc.contributor.author
Salas Silva, Soraya
dc.contributor.author
Simoni Nieves, Arturo
dc.contributor.author
Lopez Ramirez, Jocelyn
dc.contributor.author
Bucio, Leticia
dc.contributor.author
Gómez Quiroz, Luis E.
dc.contributor.author
Gutiérrez Ruiz, María Concepción
dc.contributor.author
Roma, Marcelo Gabriel
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.date.available
2020-12-15T20:21:11Z
dc.date.issued
2019-02
dc.identifier.citation
Salas Silva, Soraya; Simoni Nieves, Arturo; Lopez Ramirez, Jocelyn; Bucio, Leticia; Gómez Quiroz, Luis E.; et al.; Cholangiocyte death in ductopenic cholestatic cholangiopathies: Mechanistic basis and emerging therapeutic strategies; Pergamon-Elsevier Science Ltd; Life Sciences; 218; 2-2019; 324-339
dc.identifier.issn
0024-3205
dc.identifier.uri
http://hdl.handle.net/11336/120527
dc.description.abstract
Among hepatic diseases, cholestatic ductopenic cholangiopathies are poorly studied, and they are rarely given the importance they deserve, especially considering their high incidence in clinical practice. Although cholestatic ductopenic cholangiopathies have different etiologies and pathogenesis, all have the same target (the cholangiocyte) and similar mechanistic basis of cell death. Cholestatic cholangiopathies are characterized, predominantly, by obstructive or functional damage in the biliary epithelium, resulting in an imbalance between proliferation and cholangiocellular death; this leads to the progressive disappearance of bile ducts, as has been shown to occur in primary sclerosing cholangitis, primary biliary cholangitis, low-phospholipid-associated cholelithiasis syndrome, cystic fibrosis-related liver disease, and drug-induced ductopenia, among other biliary disorders. This review summarizes the features of the more common ductopenic syndromes and the cellular mechanisms involved in cholengiocellular death, with focus on the main forms of cholangiocyte death described so far, namely apoptosis, autophagy, necrosis, and necroptosis. It also emphasizes the importance to study in depth the molecular mechanisms of cholengiocyte death to make possible to counteract them with therapeutic purposes. These therapeutic strategies are limited in number and efficacy at present, and this is why it is important to find complementary, safe strategies to stimulate cholangiocellular proliferation in order favor bile duct replenishment as well. Successful in finding appropriate treatments would prevent the patient from having liver transplantation as the only therapeutic alternative.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Pergamon-Elsevier Science Ltd
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.rights
info:eu-repo/semantics/restrictedAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
CHOLANGIOCYTE DEATH
dc.subject
CHOLANGIOPATHIES
dc.subject
CHOLESTASIS
dc.subject
LIVER
dc.subject.classification
Gastroenterología y Hepatología
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
Medicina Clínica
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.title
Cholangiocyte death in ductopenic cholestatic cholangiopathies: Mechanistic basis and emerging therapeutic strategies
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2020-11-19T21:50:08Z
dc.journal.volume
218
dc.journal.pagination
324-339
dc.journal.pais
Estados Unidos
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.journal.ciudad
Cambridge
dc.description.fil
Fil: Salas Silva, Soraya. Universidad Autónoma Metropolitana; México
dc.description.fil
Fil: Simoni Nieves, Arturo. Universidad Autónoma Metropolitana; México
dc.description.fil
Fil: Lopez Ramirez, Jocelyn. Universidad Autónoma Metropolitana; México
dc.description.fil
Fil: Bucio, Leticia. Universidad Autónoma Metropolitana; México. Instituto Nacional de Cardiología Ignacio Chavez; México. Universidad Nacional Autónoma de México; México
dc.description.fil
Fil: Gómez Quiroz, Luis E.. Universidad Autónoma Metropolitana; México. Instituto Nacional de Cardiología Ignacio Chavez; México. Universidad Nacional Autónoma de México; México
dc.description.fil
Fil: Gutiérrez Ruiz, María Concepción. Universidad Autónoma Metropolitana; México. Instituto Nacional de Cardiología Ignacio Chavez; México. Universidad Nacional Autónoma de México; México
dc.description.fil
Fil: Roma, Marcelo Gabriel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Fisiología Experimental. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Fisiología Experimental; Argentina
dc.journal.title
Life Sciences
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/https://doi.org/10.1016/j.lfs.2018.12.044
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/abs/pii/S0024320518308373
Archivos asociados